Effects of statins on the secretion of human serum albumin in cultured HepG2 cells

Journal of Biomedical Science

Volumn 16, Issue 1, 2009, Pages

  Ha, Chung Eun ^a   Ha, Ji Sook ^a   Theriault, Andre G ^a   Bhagavan, Nadhipuram V ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HUMAN SERUM ALBUMIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; SERUM ALBUMIN;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CHOLESTEROL SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; SECRETION;

CARDIOVASCULAR DISEASES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; PRAVASTATIN; SERUM ALBUMIN; SIMVASTATIN;

EID: 64749103622     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-16-32     Document Type: Article

References (38)

1. Regulation of the mevalonate pathway. JL Goldstein MS Brown, Nature 1990 343 6257 425 30 10.1038/343425a0 1967820
2. Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. H Matsuno M Takei H Hayashi K Nakajima A Ishisaki O Kozawa, J Cardiovasc Pharmacol 2004 43 3 333 40 10.1097/00005344-200403000- 00002 15076215
3. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. T Maeda T Kawane N Horiuchi, Endocrinology 2003 144 2 681 92 10.1210/en.2002-220682 12538631
4. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. MH Shishehbor RJ Aviles ML Brennan X Fu M Goormastic GL Pearce N Gokce JF Keaney Jr MS Penn DL Sprecher JA Vita SL Hazen, Jama 2003 289 13 1675 80 10.1001/jama.289.13.1675 12672736
5. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. L Kalinowski LW Dobrucki V Brovkovych T Malinski, Circulation 2002 105 8 933 8 10.1161/hc0802.104283 11864921
6. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. L Lacoste JY Lam J Hung G Letchacovski CB Solymoss D Waters, Circulation 1995 92 11 3172 7 7586300
7. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Y Kureishi Z Luo I Shiojima A Bialik D Fulton DJ Lefer WC Sessa K Walsh, Nat Med 2000 6 9 1004 10 10.1038/79510 10973320
8. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. E Kojro G Gimpl S Lammich W Marz F Fahrenholz, Proc Natl Acad Sci USA 2001 98 10 5815 20 11309494 10.1073/pnas.081612998
9. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. MH Shishehbor ML Brennan RJ Aviles X Fu MS Penn DL Sprecher SL Hazen, Circulation 2003 108 4 426 31 10.1161/01.CIR.0000080895. 05158.8B 12860913
10. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. CP Cannon E Braunwald CH McCabe DJ Rader JL Rouleau R Belder SV Joyal KA Hill MA Pfeffer AM Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators, N Engl J Med 2004 350 15 1495 504 10.1056/NEJMoa040583 15007110
11. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. JC LaRosa SM Grundy DD Waters C Shear P Barter JC Fruchart AM Gotto H Greten JJ Kastelein J Shepherd NK Wenger Treating to New Targets (TNT) Investigators, N Engl J Med 2005 352 14 1425 35 10.1056/NEJMoa050461 15755765
12. Serum albumin, coronary heart disease, and death. RF Gillum DM Makuc, Am Heart J 1992 123 2 507 13 10.1016/0002-8703(92)90667-K 1736588
13. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. LP Fried RA Kronmal AB Newman DE Bild MB Mittelmark JF Polak JA Robbins JM Gardin, Jama 1998 279 8 585 92 10.1001/jama.279.8.585 9486752
14. Assessment of serum albumin concentration as a risk factor for stroke and coronary disease in African Americans and whites. RF Gillum, J Natl Med Assoc 2000 92 1 3 9 10800280
15. Relation between serum albumin concentration and stroke incidence and death: the NHANES I Epidemiologic Follow-up Study. RF Gillum DD Ingram DM Makuc, Am J Epidemiol 1994 140 10 876 88 7977275
16. Association of serum albumin and mortality risk. P Goldwasser J Feldman, J Clin Epidemiol 1997 50 6 693 703 10.1016/S0895-4356(97)00015-2 9250267
17. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. LH Kuller JE Eichner TJ Orchard GA Grandits L McCallum RP Tracy, Am J Epidemiol 1991 134 11 1266 77 1755441
18. Serum albumin level as a predictor of incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. JJ Nelson D Liao AR Sharrett AR Folsom LE Chambless E Shahar M Szklo J Eckfeldt G Heiss, Am J Epidemiol 2000 151 5 468 77 10707915
19. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. S Volpato SG Leveille MC Corti TB Harris JM Guralnik, J Am Geriatr Soc 2001 49 9 1142 7 10.1046/j.1532-5415.2001.49229.x 11559371
20. Human serum albumin and its structural variants mediate cholesterol efflux from cultured endothelial cells. JS Ha CE Ha JT Chao CE Petersen A Theriault NV Bhagavan, Biochim Biophys Acta 2003 1640 2-3 119 28 12729921
21. All about albumin: Biochemsitry, Genetics, and Medical Applications. T Peters Jr, San Diego: Academic Press Inc 1996 1 1 187
22. Involvement of oxysterols and lysophosphatidylcholine in the oxidized LDL-induced impairment of serum albumin synthesis by HEPG2 cells. E Bourdon N Loreau J Davignon L Bernier D Blache, Arterioscler Thromb Vasc Biol 2000 20 12 2643 50 11116066
23. Statin inhibition of HMG-CoA reductase: a 3-dimensional view. E Istvan, Atheroscler Suppl 2003 4 1 3 8 10.1016/S1567-5688(03)00003-5 12714031
24. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. ES Istvan M Palnitkar SK Buchanan J Deisenhofer, Embo J 2000 19 5 819 30 10698924 10.1093/emboj/19.5.819
25. The structure of the catalytic portion of human HMG-CoA reductase. ES Istvan J Deisenhofer, Biochim Biophys Acta 2000 1529 1-3 9 18 11111074
26. Characterization of lipoproteins produced by the human liver cell line, Hep G2, under defined conditions. RN Thrift TM Forte BE Cahoon VG Shore, J Lipid Res 1986 27 3 236 50 3016129
27. Effects of gamma-tocotrienol on ApoB synthesis, degradation, and secretion in HepG2 cells. A Theriault Q Wang A Gapor K Adeli, Arterioscler Thromb Vasc Biol 1999 19 3 704 12 10073977
28. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. M Takemoto JK Liao, Arterioscler Thromb Vasc Biol 2001 21 11 1712 9 10.1161/hq1101.098486 11701455
29. Statins and the acute-phase response. RS Munford, N Engl J Med 2001 344 26 2016 8 10.1056/NEJM200106283442609 11430332
30. Are statins anti-inflammatory? GJ Blake PM Ridker, Curr Control Trials Cardiovasc med 2000 1 3 161 165 11714433 10.1186/CVM-1-3-161
31. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. D Li H Chen F Romeo T Sawamura T Saldeen JL Mehta, J Pharmacol Exp Ther 2002 302 2 601 5 10.1124/jpet.102.034959 12130721
32. Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. V Bonn RC Cheung B Chen C Taghibiglou SC Van Iderstine K Adeli, Atherosclerosis 2002 163 1 59 68 10.1016/S0021-9150(01)00754-7 12048122
33. Association between serum albumin and mortality from cardiovascular disease, cancer, and other causes. A Phillips AG Shaper PH Whincup, Lancet 1989 2 8677 1434 6 10.1016/S0140-6736(89)92042-4 2574367
34. Albumin levels as a predictor of mortality in the healthy elderly. H Klonoff-Cohen EL Barrett-Connor SL Edelstein, J Clin Epidemiol 1992 45 3 207 12 10.1016/0895-4356(92)90080-7 1569417
35. Evidence for the existence of non-esterified cholesterol carried by albumin in rat serum. G Deliconstantinos C Tsopanakis P Karayiannakos G Skalkeas, Atherosclerosis 1986 61 1 67 75 10.1016/0021-9150(86)90114-0 3015157
36. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. JE Edwards RA Moore, BMC Fam Pract 2003 4 18 14969594 10.1186/1471-2296-4-18
37. Pleiotropic effects of statins. JK Liao U Laufs, Annu Rev Pharmacol Toxicol 2005 45 89 118 10.1146/annurev.pharmtox.45.120403.095748 15822172
38. Suppression of albumin enhancer activity by H-ras and AP-1 in hepatocyte cell lines. J Hu HC Isom, Mol Cell Biol 1994 14 3 1531 43 8114691